Alume Biosciences delivers positive topline results for three pivotal trials of Bevonescein, advancing toward NDA submission with US FDA in 2H 2026 Even with meticulous technique, surgeons are limited ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果一些您可能无法访问的结果已被隐去。
显示无法访问的结果